MYOGENICA INC.
A revolutionary, universal stem cell platform for muscle regeneration
SAINT PAUL, United States · Founded 2023 · $1.6M raised
- Headquarters
- SAINT PAUL, Minnesota
- Employees
- 1–10
- Founded
- 2023
- Business Model
- B2B
- Website
- myogenica.com
- Total Funding
- $1.6M
About
Myogenica is a biotechnology company spun out of the University of Minnesota developing MyoPAXon, a universal induced pluripotent stem cell (iPSC) platform for muscle regeneration. The MyoPAXon platform leverages PAX7 expression — found exclusively in muscle stem cells — to regenerate muscle and improve function in multiple forms of muscular dystrophy, including Duchenne, limb girdle, and facioscapulohumeral muscular dystrophy (FSHD).
Summary
MYOGENICA INC. is a Biotech company based in SAINT PAUL, United States, founded in 2023. It has raised $1.6M in total.
Funding History
No funding data available yet.
Know something? Help us improve our data.
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...